Although PARP inhibitors are now exploited clinically to treat BRCA1- and BRCA2-mutated cancers, the nature of the DNA structures on which PARP enzymes are “trapped” by these inhibitors is unclear. The gene discussed is BRCA2; the disease is cancer.